Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Response rates to mail surveys published in medical journals

David A. Asch, M. Kathryn Jedrziewski, Nicholas A. Christakis · Journal of Clinical Epidemiology · 1997 · 2.1K citations

Social Sciences, Health Sciences, Epidemiology +12

Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?

Sophie Postel‐Vinay, Carlos Gomez‐Roca, L Rhoda Molife et al. · Journal of Clinical Oncology · 2011 · 138 citations

Pharmacy, Pharmacology, Cancer Drug Toxicity Management +16

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study

Annette Wigertz, Johan Ahlgren, Marit Holmqvist et al. · Breast Cancer Research and Treatment · 2012 · 125 citations

Medicine, Oncology, Breast Oncology +15

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

Christopher M. Booth, A. Hilary Calvert, Giuseppe Giaccone et al. · European Journal of Cancer · 2007 · 109 citations

Medicine, Oncology, Cancer Pharmacology +15